Benitec Biopharma Inc (BNTC)
9.49
+0.02
(+0.21%)
USD |
NASDAQ |
May 17, 16:00
8.91
-0.58
(-6.11%)
After-Hours: 20:00
Benitec Biopharma Total Liabilities (Quarterly): 3.499M for March 31, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.499M |
| December 31, 2023 | 5.883M |
| September 30, 2023 | 4.745M |
| June 30, 2023 | 4.262M |
| March 31, 2023 | 3.507M |
| December 31, 2022 | 2.911M |
| September 30, 2022 | 3.502M |
| June 30, 2022 | 3.091M |
| March 31, 2022 | 2.544M |
| December 31, 2021 | 3.178M |
| September 30, 2021 | 2.361M |
| June 30, 2021 | 1.369M |
| March 31, 2021 | 2.498M |
| December 31, 2020 | 0.887M |
| September 30, 2020 | 1.18M |
| June 30, 2020 | 1.349M |
| Date | Value |
|---|---|
| June 30, 2019 | 2.641M |
| December 31, 2018 | 1.514M |
| June 30, 2018 | 1.906M |
| March 31, 2018 | 1.316M |
| December 31, 2017 | 1.420M |
| September 30, 2017 | 1.361M |
| June 30, 2017 | 0.8914M |
| March 31, 2017 | 0.8967M |
| December 31, 2016 | 1.005M |
| September 30, 2016 | 0.7322M |
| June 30, 2016 | 0.7864M |
| March 31, 2016 | 1.706M |
| December 31, 2015 | 0.7303M |
| June 30, 2015 | 1.259M |
| December 31, 2014 | 0.5881M |
| June 30, 2014 | 1.546M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
0.887M
Minimum
Dec 2020
5.883M
Maximum
Dec 2023
2.906M
Average
2.911M
Median
Dec 2022
Total Liabilities (Quarterly) Benchmarks
| Galectin Therapeutics Inc | 96.98M |
| TG Therapeutics Inc | 213.21M |
| BioVie Inc | 14.00M |
| Jaguar Health Inc | 43.57M |
| Entero Therapeutics Inc | 3.280M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 15.00M |
| Shareholders Equity (Quarterly) | 11.50M |